Werewolf Therapeutics, Inc. HOWL 深 滬
已收盤 10-24 16:00:00 美东时间
1.77
+0.200
+12.74%
華盛通- 最 高1.83
- 今 開1.60
- 成交量 106.51万股
- 最 低 1.59
- 昨 收 1.57
- 總市值 8094.03万
- 52周最高 2.52
- 市盈率 靜 --
- 換手率 2.33%
- 52周最低 0.595
- 委 比 83.20%
- 總股本 4572.90万
- 歷史最高 23.99
- 量 比 1.85
- 振 幅 15.29%
- 歷史最低 0.595
- 每 手 1
- 風險率 0.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, a conditionally activated IL-2 INDUKINE therapy, for the treatment of locally advanced or metastatic cutaneous melanoma following standard immunotherapy. This designation aims to expedite the development of drugs addressing serious unmet medical needs. WTX-124 is being evaluated in a Phase 1/1b trial targeting various solid tumors, aiming to stimulate anti-tumor i...
10-08 12:00
Werewolf Therapeutics Faces Nasdaq Compliance Challenge
The latest announcement is out from Werewolf Therapeutics ( ($HOWL) ). Werewolf...
10-07 05:00
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
<p>Werewolf Therapeutics announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting from November 5-9, 2025, in National Harbor, Maryland. The posters highlight advancements in conditionally activated therapeutics engineered to stimulate the body’s immune system for cancer treatment. Key topics include enhanced antitumor activity without systemic toxicity, a masking approach to ...
10-03 13:00
【膜杰作】STEAP：二十年磨一剑，或为实体瘤治疗的下一突破口
（来源：ACROBiosystems官方） 转自：ACROBiosystems官方 在全球抗癌药物研发中，细胞表面靶点始终占据核心地位。STEAP（前列腺六次跨...
09-17 17:43
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Werewolf Therapeutics, Inc., a biopharmaceutical company, announced that its President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The event will be webcast live with an archive available for 90 days. The company specializes in developing immune-stimulating therapeutics for cancer and immu...
09-02 12:00
美股大行评级 | 潜在涨幅17.9%！Stifel维持英伟达"买入"评级，目标价升至212美元；美银首予Figma"中性"评级，目标价85美元
今日重点评级关注：Stifel：维持英伟达"买入"评级，目标价从202美元升至212美元；蒙特利尔银行：维持Sabra Health Care REIT"与大市齐平"评级，目标价从19美元升至22美元
08-26 10:29
JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3
JMP Securities analyst Reni J. Benjamin maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and lowers the price target from $4 to $3.
08-21 21:11
Werewolf Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.36 percent. This is a 6.98 percent increase over losses of $(0.43) per share
08-14 19:18
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics provides updates on its clinical trials, including interim data readouts for WTX-124 in late 2025 and plans to engage with FDA for registrational pathways. WTX-330's Phase 1b/2 trial is enrolling, with dosing regimen to be determined by year-end. The company introduces WTX-1011, its first INDUCER T-cell engager targeting STEAP1 for prostate cancer, showcasing promising preclinical data. Financially, the company has $77.6 mil...
08-14 11:00
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics' Chief Medical Officer, Randi Isaacs, will speak at the KidneyCAN 7th Annual Summit on July 17-18 in Boston. Her presentation will focus on the company's innovative approach to conditionally activated cytokines, specifically WTX-124, a tumor-activated IL-2 molecule designed to enhance anti-tumor activity while reducing systemic side effects. The company is currently enrolling patients in a clinical trial for advanced or meta...
07-09 12:00
